glp1 tirzepatide Tirzepatide: A Breakthrough Approach to Losing Weight Safely Tirzepatide | TRAVA

Persons with type 2 diabetes tend to also have some degree of increased body weight or obesity and we know that achieving at least 5% body weight helps to improve glucose and cardiometabolic risk factors. MNT spoke with Jennifer Cheng, DO, chief of endocrinology at Hackensack Meridian Jersey Shore University Medical Center in New Jersey who was not involved in this study who commented it is important to find new options for the treatment of type 2 diabetes and give patients the choice of administering either via subcutaneous injections or just a daily pill

Supplies Needed Estimated requirements based on an 816 week protocol at 2 mg daily dosage : Tesamorelin 10 mg Vials 8 weeks: ~11 vials 12 weeks: ~17 vials 16 weeks: ~22 vials Insulin Syringes (U-100) 1 per day 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL Bottles) ~3.0 mL per vial 8 weeks: ~4 bottles 12 weeks: ~6 bottles 16 weeks: ~7 bottles Alcohol Swabs 2 per day (vial + injection site) 8 weeks: ~112 swabs 12 weeks: ~168 swabs 16 weeks: ~224 swabs Protocol Overview A simplified overview of the daily regimen: Goal: Reduce visceral fat and improve metabolic health Schedule: Daily injections for 1226 weeks Dosage: 2 mg daily after initial titration Reconstitution: 3.0 mL per vial Storage: Refrigerate

Its unique mechanism targets both GLP-1 and GIP receptors, helping to suppress appetite, slow digestion, and improve insulin sensitivity

Research indicates that up to one-third of this weight loss is non-fat mass muscle and bone mass (lean mass)